Literature DB >> 23333038

Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients?

Jens Walldorf1, Annette Krummenerl, Kristin Engler, Juliane Busch, Matthias M Dollinger, Thomas Seufferlein, Jörg G Albert.   

Abstract

BACKGROUND AND AIMS: Osteoporosis is a frequent complication of inflammatory bowel disease (IBD). It may be related to IBD itself or to its therapy. In this study, the quality of care regarding diagnosis and treatment of osteoporosis was examined.
METHODS: In this retrospective, monocentric study 293 consecutive patients with IBD (98 ulcerative colitis, 195 Crohn's disease) were included. Information on age, gender, weight, nicotine abuse, course, disease pattern and medication was assessed, results of dual X-ray absorptiometry (DEXA-scan) were evaluated.
RESULTS: DEXA-scan was performed in 174 patients (59 male, 115 female). Bone mineral density (BMD) was impaired in 38.5% of these patients. Male patients were diagnosed more often with osteopenia or osteoporosis than females (55.9% vs. 29.6%, p=0.03) and had a risk of bone disease comparable to postmenopausal women. Additionally, duration of corticosteroid treatment and IBD were identified as risk factors for osteoporosis. Follow up DEXA-scan demonstrated an overall deterioration of BMD in patients with normal baseline results.
CONCLUSIONS: While in general, women are considered at higher risk for osteoporosis, male patients had a higher risk of impaired BMD, especially when under treatment with corticosteroids. The high incidence of reduced BMD supports the recommendation to screen patients with IBD at an early stage of disease, although a possible bias has to be considered for patients at a tertial referral centre for IBD. Patients with normal baseline DEXA-scan were still at risk to develop bone disease and it seems advisable to monitor patients with IBD for reduced BMD continually.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colitis ulcerosa; Crohn's disease; Inflammatory bowel disease; Osteoporosis

Mesh:

Year:  2013        PMID: 23333038     DOI: 10.1016/j.crohns.2012.12.008

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  5 in total

1.  Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients.

Authors:  Bincy P Abraham; Preethi Prasad; Hoda M Malaty
Journal:  Dig Dis Sci       Date:  2014-03-12       Impact factor: 3.199

Review 2.  Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives.

Authors:  Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli; Markus F Neurath; Helmut Neumann
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 3.  European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.

Authors:  Stephan C Bischoff; Rocco Barazzoni; Luca Busetto; Marjo Campmans-Kuijpers; Vincenzo Cardinale; Irit Chermesh; Ahad Eshraghian; Haluk Tarik Kani; Wafaa Khannoussi; Laurence Lacaze; Miguel Léon-Sanz; Juan M Mendive; Michael W Müller; Johann Ockenga; Frank Tacke; Anders Thorell; Darija Vranesic Bender; Arved Weimann; Cristina Cuerda
Journal:  United European Gastroenterol J       Date:  2022-08-12       Impact factor: 6.866

4.  Soybean Meal-Dependent Acute Intestinal Inflammation Delays Osteogenesis in Zebrafish Larvae.

Authors:  Marta Carnovali; Giuseppe Banfi; Giovanni Porta; Massimo Mariotti
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

5.  High detection rate of osteoporosis with screening of a general hospitalized population: a 6-year study in 6406 patients in a university hospital setting.

Authors:  Olivier Malaise; Marie Detroz; Mathieu Leroy; Lorenzo Leonori; Laurence Seidel; Michel G Malaise
Journal:  BMC Musculoskelet Disord       Date:  2020-02-10       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.